Catalog: | C-FC-4202A |
Product Type: | FCM Antibody |
Size: | 25 Tests/100 Tests |
Concentration: | 10 μl/Test, 0.1 mg/ml |
Reactivity: | Human |
Specificity: | Human LYPD3 |
Analysis mode: | FCM |
Host: | Rabbit |
Clonality: | Monoclonal |
Isotype: | IgG |
Alternate names: | LY6/PLAUR domain containing 3 |
Form: | Liquid |
Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Storage: | This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! |
Purification method: | Protein A |
Conjugation: | APC |
Immunogen: | Recombinant Human C4.4A / LYPD3 protein |
Buffer: | Aqueous solution containing 0.5% BSA and 0.03%ProClin300 |
Ly6 / PLAUR domain-containing protein 3, also known as GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein, MIG-C4, and LYPD3, is a cell membrane protein that contains two UPAR/Ly6 domains. Human LYPD3 contains two UPAR/Ly6 domains. LYPD3 is expressed in the placenta, skin, and urothelium. It is found in suprabasal keratinocytes of chronic wounds. Weak expression of LYPD3 is found in the esophagus and peripheral blood mononuclear cells. It is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. High expression of LYPD3 is found in the tumor component of some noninvasive superficial lesions and invasive and metastatic urothelial cancers. LYPD3 is up-regulated in migrating keratinocytes during epithelisation of incisional skin wounds. LYPD3 supports cell migration. It may be involved in urothelial cell-matrix interactions. It may also be involved in tumor progression
Copyright © 2025 Creative Biogene. All rights reserved.